AIDS task force grapples with faster access to protease drugs.
Mascolini
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D018791:CD4 Lymphocyte Count; D017277:Drug Approval; D015195:Drug Design; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir; D019259:Lamivudine; D011725:Pyridines / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D011725:Pyridines; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine